HK1254525A1 - 治療組合物、組合和使用方法 - Google Patents
治療組合物、組合和使用方法Info
- Publication number
- HK1254525A1 HK1254525A1 HK18113775.4A HK18113775A HK1254525A1 HK 1254525 A1 HK1254525 A1 HK 1254525A1 HK 18113775 A HK18113775 A HK 18113775A HK 1254525 A1 HK1254525 A1 HK 1254525A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combinations
- methods
- therapeutic compositions
- therapeutic
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186197P | 2015-06-29 | 2015-06-29 | |
PCT/US2016/040080 WO2017004192A1 (en) | 2015-06-29 | 2016-06-29 | Therapeutic compositions, combinations, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1254525A1 true HK1254525A1 (zh) | 2019-07-19 |
Family
ID=57609144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18113775.4A HK1254525A1 (zh) | 2015-06-29 | 2018-10-29 | 治療組合物、組合和使用方法 |
Country Status (13)
Country | Link |
---|---|
US (3) | US10532056B2 (zh) |
EP (1) | EP3313404B1 (zh) |
JP (3) | JP2018519327A (zh) |
KR (1) | KR20180100539A (zh) |
CN (2) | CN114209841A (zh) |
AU (3) | AU2016286091B2 (zh) |
CA (1) | CA2991044A1 (zh) |
EA (1) | EA201890161A1 (zh) |
HK (1) | HK1254525A1 (zh) |
IL (1) | IL256652A (zh) |
MX (2) | MX2018000288A (zh) |
WO (1) | WO2017004192A1 (zh) |
ZA (1) | ZA201800572B (zh) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
TR201907147T4 (tr) | 2013-07-18 | 2019-06-21 | Taiho Pharmaceutical Co Ltd | Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç. |
BR112017019559B1 (pt) | 2015-03-13 | 2020-08-04 | Cytomx Therapeutics, Inc | Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
MA42447A (fr) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation |
EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR TREATING MALIGNANT TUMORS |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
KR102490278B1 (ko) * | 2017-02-07 | 2023-01-18 | 각코우호우징 사이타마이카다이가쿠 | 암 면역요법의 임상 효과 예측을 위한 면역 바이오마커 |
BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
US11452764B2 (en) * | 2017-07-21 | 2022-09-27 | University Of North Dakota | Inhibiting FAK-AKT interaction to inhibit metastasis |
KR20210004966A (ko) * | 2018-03-12 | 2021-01-13 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 암 치료를 위한 화학-면역요법 강화용 열량 제한 모방물질의 용도 |
AU2019239404B2 (en) | 2018-03-19 | 2021-12-23 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
CN110960679A (zh) * | 2018-09-28 | 2020-04-07 | 江苏康缘药业股份有限公司 | 一种抗肿瘤的药物组合物及其应用 |
BR112021012682A2 (pt) * | 2018-12-27 | 2021-09-08 | Hinova Pharmaceuticals Inc. | Inibidor de fak e combinação de fármaco do mesmo |
CN109675040B (zh) * | 2018-12-31 | 2021-07-30 | 清华大学 | 治疗乳腺癌的组合物及其应用 |
KR20210130774A (ko) * | 2019-02-28 | 2021-11-01 | 다이호야쿠힌고교 가부시키가이샤 | 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 |
WO2020202005A1 (en) * | 2019-04-02 | 2020-10-08 | Inxmed (Shanghai) Co., Ltd. | Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors |
TWI757716B (zh) * | 2019-04-15 | 2022-03-11 | 禾榮科技股份有限公司 | 微創型中子束產生裝置及微創型中子捕獲治療系統 |
CN110201171A (zh) * | 2019-06-18 | 2019-09-06 | 北京大学 | Fak抑制剂在治疗常染色体显性遗传多囊肾病中的应用 |
JP2022538690A (ja) * | 2019-07-05 | 2022-09-05 | タンボ・インコーポレイテッド | トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
WO2021047783A1 (en) * | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
PE20221259A1 (es) * | 2019-11-18 | 2022-08-16 | Inxmed Nanjing Co Ltd | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras |
CN114728005A (zh) * | 2019-11-28 | 2022-07-08 | 应世生物科技(南京)有限公司 | Bi853520在癌症治疗中的用途 |
CA3168648A1 (en) * | 2020-01-31 | 2021-08-05 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
BR112022015150A2 (pt) * | 2020-02-05 | 2022-10-11 | Inxmed Nanjing Co Ltd | Combinação de bi853520 com fármacos quimioterápicos |
WO2021161994A1 (ja) | 2020-02-14 | 2021-08-19 | 富士フイルム株式会社 | 光結合システムおよび光通信デバイス |
CN116056699A (zh) * | 2020-07-13 | 2023-05-02 | 维瑞斯特姆股份有限公司 | 用于治疗异常细胞生长的组合疗法 |
WO2022125652A1 (en) * | 2020-12-08 | 2022-06-16 | Cornell University | Methods of inducing an immunomodulatory tumor response |
AU2021396314A1 (en) * | 2020-12-11 | 2023-06-29 | Materia Therapeutics Inc. | Cancer treatment using bosentan in combination with a checkpoint inhibitor |
TW202313044A (zh) * | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技(南京)有限公司 | In10018與pld的聯用 |
WO2023193705A1 (zh) * | 2022-04-07 | 2023-10-12 | 深圳微芯生物科技股份有限公司 | 西奥罗尼在抗胰腺癌中的用途 |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
TW202408528A (zh) | 2022-06-24 | 2024-03-01 | 大陸商應世生物科技(南京)有限公司 | 治療腫瘤的藥物組合及用途 |
WO2024051679A1 (zh) * | 2022-09-05 | 2024-03-14 | 应世生物科技(南京)有限公司 | Fak抑制剂及egfr-tki的药物组合及用途 |
TW202412766A (zh) * | 2022-09-16 | 2024-04-01 | 大陸商應世生物科技(南京)有限公司 | Fak抑制劑及拓撲異構酶抑制劑的藥物組合及用途 |
WO2024067631A1 (zh) * | 2022-09-30 | 2024-04-04 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US20030009158A1 (en) | 2001-07-09 | 2003-01-09 | Perricone Nicholas V. | Skin treatments using blue and violet light |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
FI20030976A (fi) | 2003-06-30 | 2004-12-31 | M Real Oyj | Päällystetty pohjapaperi ja menetelmä päällystetyn pohjapaperin valmistamiseksi |
EP1761132B1 (en) | 2004-06-30 | 2011-11-23 | Cadbury Holdings Limited | Chewing gum comprising flavor emulsion |
CN101679264A (zh) | 2007-03-16 | 2010-03-24 | 斯克里普斯研究学院 | 粘着斑激酶抑制剂 |
GEP20125581B (en) | 2007-04-18 | 2012-07-25 | Pfizer Prod Inc | Sulfonyl amide derivatives for treatment of abnormal cell growth |
WO2009105498A1 (en) | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
EP2303861B1 (en) | 2008-06-17 | 2014-04-23 | AstraZeneca AB | Pyridine compounds |
US20140155410A1 (en) | 2008-10-27 | 2014-06-05 | Glaxosmithkline Llc | Pyrazolylaminopyridines as inhibitors of fak |
JO3067B1 (ar) | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
EP2726079A4 (en) * | 2011-06-28 | 2014-12-17 | Glaxosmithkline Ip No 2 Ltd | METHOD OF ADMINISTRATION AND TREATMENT |
US20140105891A1 (en) * | 2012-10-05 | 2014-04-17 | Cerulean Pharma Inc. | Treatment of cancer |
US20150118247A1 (en) | 2013-10-25 | 2015-04-30 | Nodality, Inc. | Methods and compositions for immunomodulation |
KR102196884B1 (ko) * | 2013-11-01 | 2020-12-30 | 화이자 인코포레이티드 | 전립선-연관 항원의 발현을 위한 벡터 |
WO2015120289A1 (en) | 2014-02-07 | 2015-08-13 | Verastem, Inc. | Methods and compositions for treating abnormal cell growth |
WO2017201043A1 (en) | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
-
2016
- 2016-06-29 WO PCT/US2016/040080 patent/WO2017004192A1/en active Application Filing
- 2016-06-29 MX MX2018000288A patent/MX2018000288A/es unknown
- 2016-06-29 CN CN202111345764.0A patent/CN114209841A/zh active Pending
- 2016-06-29 EP EP16818676.5A patent/EP3313404B1/en active Active
- 2016-06-29 US US15/738,999 patent/US10532056B2/en active Active
- 2016-06-29 AU AU2016286091A patent/AU2016286091B2/en active Active
- 2016-06-29 EA EA201890161A patent/EA201890161A1/ru unknown
- 2016-06-29 KR KR1020187002706A patent/KR20180100539A/ko not_active Application Discontinuation
- 2016-06-29 CA CA2991044A patent/CA2991044A1/en active Pending
- 2016-06-29 CN CN201680044292.6A patent/CN108289892B/zh active Active
- 2016-06-29 JP JP2017568200A patent/JP2018519327A/ja not_active Withdrawn
-
2017
- 2017-12-28 IL IL256652A patent/IL256652A/en unknown
-
2018
- 2018-01-08 MX MX2022001165A patent/MX2022001165A/es unknown
- 2018-01-26 ZA ZA2018/00572A patent/ZA201800572B/en unknown
- 2018-10-29 HK HK18113775.4A patent/HK1254525A1/zh unknown
-
2019
- 2019-11-25 US US16/694,384 patent/US11564927B2/en active Active
-
2021
- 2021-04-19 AU AU2021202379A patent/AU2021202379B2/en active Active
- 2021-09-03 JP JP2021143803A patent/JP2021183650A/ja not_active Withdrawn
-
2022
- 2022-12-21 US US18/085,792 patent/US20240000790A1/en active Pending
-
2023
- 2023-08-09 AU AU2023214272A patent/AU2023214272A1/en active Pending
-
2024
- 2024-06-21 JP JP2024100476A patent/JP2024111247A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20180100539A (ko) | 2018-09-11 |
US11564927B2 (en) | 2023-01-31 |
EA201890161A1 (ru) | 2018-06-29 |
JP2021183650A (ja) | 2021-12-02 |
AU2021202379B2 (en) | 2023-05-11 |
AU2021202379A1 (en) | 2021-05-13 |
US20180177788A1 (en) | 2018-06-28 |
WO2017004192A1 (en) | 2017-01-05 |
US20240000790A1 (en) | 2024-01-04 |
EP3313404A1 (en) | 2018-05-02 |
CA2991044A1 (en) | 2017-01-05 |
IL256652A (en) | 2018-02-28 |
US20200330471A1 (en) | 2020-10-22 |
CN114209841A (zh) | 2022-03-22 |
JP2024111247A (ja) | 2024-08-16 |
MX2022001165A (es) | 2022-02-22 |
AU2016286091B2 (en) | 2021-02-04 |
BR112017028519A2 (pt) | 2018-08-28 |
ZA201800572B (en) | 2023-12-20 |
EP3313404A4 (en) | 2019-08-07 |
CN108289892A (zh) | 2018-07-17 |
CN108289892B (zh) | 2021-11-23 |
MX2018000288A (es) | 2018-11-09 |
JP2018519327A (ja) | 2018-07-19 |
AU2023214272A1 (en) | 2023-08-31 |
EP3313404B1 (en) | 2024-09-04 |
AU2016286091A1 (en) | 2018-02-22 |
US10532056B2 (en) | 2020-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254525A1 (zh) | 治療組合物、組合和使用方法 | |
IL286316A (en) | New micro-dystrophins and related method of use | |
IL277069B (en) | Modified aminopurine compounds, their compositions and methods of treatment with them | |
IL259246A (en) | Preparations containing pharmaceutical substances and methods of using them | |
HK1259372A1 (zh) | 治療化合物、其組合物及使用方法 | |
SG11201609254YA (en) | Therapeutic placental compositions, methods of making and methods of use | |
HK1258393A1 (zh) | 抗菌藥物組合的組合物和使用方法 | |
HK1243354B (zh) | 新穎碘伏組合物及其使用方法 | |
IL254783B (en) | Combinations for deworming methods for using them | |
HK1255221A1 (zh) | 使用卡多曲組合物進行治療的方法 | |
IL257458A (en) | dpep-1 binding compositions and methods of use | |
PL2998311T3 (pl) | Mieszanina alkiloglikozydów, ich wytwarzanie i zastosowanie | |
HK1258056A1 (zh) | 治療性化合物和其使用方法 | |
GB201511799D0 (en) | Composition and methods of treatment | |
HK1243404A1 (zh) | 色酰胺組合物和使用方法 | |
HK1258765A1 (zh) | 治療性化合物、組合物和它們的使用方法 | |
HK1248527A1 (zh) | 牙科組合物和使用方法 | |
IL258431A (en) | Deimmunized therapeutic compositions and methods | |
PL3341481T3 (pl) | Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne | |
ZA201802201B (en) | Novel formulation and treatment methods | |
HK1259196A1 (zh) | 延遲釋放製劑、其製備方法和用途 | |
GB201419559D0 (en) | Therapeutic compositions and methods | |
GB201521083D0 (en) | Compositions for treatment and methods thereof | |
GB201508518D0 (en) | Hair treatment compositions and methods | |
GB201409262D0 (en) | Hair treatment compositions and methods |